title: Review of the potential effects of three commonly used antineoplastic and immunosuppressive drugs (cyclophosphamide, azathioprine, doxorubicin on the embryo and placenta).
authors.affiliation: Oncogenetic Laboratory, Department of Medicine A, Sapir Medical Center, Kfar-Saba, Israel.
authors.forename: Shelly Tartakover
authors.initials: ST
authors.lastname: Matalon
authors.forename: Asher
authors.initials: A
authors.lastname: Ornoy
authors.forename: Michael
authors.initials: M
authors.lastname: Lishner
mesh_terms: D000014:Abnormalities, Drug-Induced; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D001379:Azathioprine / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D004317:Doxorubicin / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D005314:Embryonic and Fetal Development / Q000187:drug effects; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D023421:Models, Animal; D010920:Placenta / Q000187:drug effects; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D011261:Pregnancy Trimester, First; D018675:Toxicity Tests
chemical_list: D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D004317:Doxorubicin; D003520:Cyclophosphamide; D001379:Azathioprine